White Papers

Dr. Peter Chiu on Fast, Reliable, Early Screening for Potentially Arrhythmia-Causing HERG Inhibitors

When Ricerca Biosciences recruited Dr. Peter Chiu, the company put itself in an excellent position to address the compound screening aspects of one of today’s most urgent issues in cardiovascular safety pharmacology – drug-induced prolongation of the QT interval, which may contribute to cardiac arrhythmias (i.e., lack of rhythmic contractions of the heart) and death.